NADAC acquisition cost data for ETHOSUXIMIDE 250 MG CAPSULE. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 23155053201 | $0.4009 | 2022-12-21 | Rx |
| 42806071101 | $0.4009 | 2022-12-21 | Rx |
| 59762225002 | $0.4009 | 2022-12-21 | Rx |
| 61748002501 | $0.4009 | 2022-12-21 | Rx |
| 64380087806 | $0.4009 | 2022-12-21 | Rx |
| 69452015220 | $0.4009 | 2022-12-21 | Rx |
| 23155053201 | $0.4009 | 2022-12-21 | Rx |
| 42806071101 | $0.4009 | 2022-12-21 | Rx |
| 59762225002 | $0.4009 | 2022-12-21 | Rx |
| 61748002501 | $0.4009 | 2022-12-21 | Rx |
Generic: Ethosuximide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.5M | 15,206 | 2,068 | $1.12 |
| 2020 | $2.6M | 15,035 | 2,072 | $1.09 |
| 2021 | $2.4M | 14,585 | 2,111 | $1.01 |
| 2022 | $2.2M | 14,656 | 2,092 | $0.9134 |
| 2023 | $2.0M | 14,924 | 2,145 | $0.8542 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $131.9K | 793 | 136 |
| New York | $114.8K | 867 | 129 |
| Florida | $114.3K | 812 | 124 |
| Pennsylvania | $110.8K | 780 | 103 |
| Texas | $96.2K | 753 | 139 |
| Ohio | $96.0K | 725 | 105 |
| Minnesota | $86.9K | 682 | 78 |
| Illinois | $85.0K | 677 | 91 |
| Michigan | $80.9K | 596 | 89 |
| Indiana | $78.2K | 510 | 73 |
| Massachusetts | $71.8K | 523 | 78 |
| North Carolina | $69.2K | 444 | 74 |
| Washington | $67.5K | 456 | 68 |
| Virginia | $44.9K | 284 | 49 |
| Missouri | $44.0K | 332 | 49 |
| Wisconsin | $42.7K | 335 | 49 |
| Tennessee | $42.2K | 261 | 46 |
| Kansas | $40.8K | 293 | 38 |
| Iowa | $37.0K | 288 | 37 |
| New Jersey | $34.7K | 264 | 42 |
| Louisiana | $34.0K | 254 | 30 |
| Arkansas | $33.4K | 263 | 35 |
| Oregon | $32.8K | 209 | 36 |
| Georgia | $31.9K | 289 | 46 |
| Oklahoma | $31.9K | 239 | 33 |
| Utah | $30.0K | 266 | 32 |
| Alabama | $29.0K | 183 | 34 |
| Arizona | $24.3K | 161 | 33 |
| Kentucky | $23.7K | 251 | 45 |
| South Carolina | $23.5K | 185 | 33 |
| Idaho | $21.1K | 168 | 28 |
| Nebraska | $20.8K | 145 | 16 |
| New Hampshire | $20.0K | 181 | 30 |
| Maine | $16.7K | 133 | 17 |
| South Dakota | $16.6K | 129 | 14 |
| Connecticut | $15.8K | 110 | 21 |
| Maryland | $15.6K | 144 | 28 |
| Colorado | $15.3K | 123 | 19 |
| Mississippi | $15.3K | 121 | 16 |
| Puerto Rico | $14.3K | 140 | 20 |
| West Virginia | $12.7K | 104 | 16 |
| Nevada | $11.3K | 56 | 12 |
| Rhode Island | $10.0K | 64 | 11 |
| North Dakota | $9.8K | 72 | N/A |
| Montana | $9.3K | 79 | 12 |
| New Mexico | $5.8K | 28 | N/A |
| Hawaii | $5.2K | 47 | N/A |
| Delaware | $5.1K | 26 | N/A |
| Vermont | $4.7K | 23 | N/A |
| Wyoming | $2.9K | 11 | N/A |
| Alaska | $1.5K | 26 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.